Gritstone bio to Participate in 43rd Annual Cowen Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Gritstone bio, a clinical-stage biotechnology firm, announced that its Co-founder and CEO, Andrew Allen, will participate in the "Novel Immuno-Oncology" panel at the Cowen 43rd Annual Healthcare Conference. The event is scheduled for March 6, 2023, from 9:10 to 10:10am ET, at the Boston Marriott Copley Place. A live webcast of the panel will be accessible, with an archived replay available for 30 days.
Gritstone is focused on developing potent vaccines targeting viral diseases and solid tumors, utilizing innovative vectors to enhance immune response. Investors and media inquiries can be directed to their respective contacts provided in the release.
Details
News Market Reaction – GRTS
The recorded move for GRTS in the trading session of this news was +0.82%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that Andrew Allen, M.D., Ph.D., Gritstone’s Co-founder, President and Chief Executive Officer will participate in the “Novel Immuno-Oncology” panel at the Cowen 43rd Annual Healthcare Conference on March 6, 2023.
Panel Details
Title: Novel I-O Corporate Panel
Date and Time: Monday, March 6, 2023 from 9:10 to 10:10am ET
Location: Boston Marriott Copley Place, 110 Huntington Ave, Boston, MA 02116
A live webcast of the panel will be available at https://ir.gritstonebio.com/investors/events. An archived replay will be accessible for 30 days following the event.
About Gritstone bio
Gritstone is working to create the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets and have programs in viral diseases and solid tumors. Independently and with our partners, we are advancing a portfolio of product candidates with the aim of improving patient outcomes and eliminating disease. www.gritstonebio.com
Gritstone Contacts
Investors:
George E. MacDougall
Director, Investor Relations & Corporate Communications
Gritstone bio, Inc.
ir@gritstone.com
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.